

## References

S-266

1. Mariados N, Sylvester J, Shah D, et al. Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. *Int J Radiat Oncol Biol Phys*. 2015;92(5):971-977. PMID 26054865
2. Hamstra DA, Mariados N, Sylvester J, et al. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. *Int J Radiat Oncol Biol Phys*. 2017;97(5):976-985. PMID 28209443
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer V2:2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf). Accessed May 16, 2019.
4. Schörghofer A, Drerup M, Kunit T, et al. Rectum-spacer related acute toxicity - endoscopy results of 403 prostate cancer patients after implantation of gel or balloon spacers. *Radiation Oncology (London, England)*. 2019;14(1):47. doi:10.1186/s13014-019-1248-6.
5. Hayes Health Technology Brief. Absorbable Perirectal Spacer (SpaceOAR System; Augmenix Inc.) During Radiation Therapy for Prostate Cancer. Lansdale, PA: Hayes, Inc; Published April 2018. Reviewed May 2019. Accessed May 2019.
6. National Institute for Health and Care Excellence (NICE). Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. NICE Interventional Procedure Guidance No. 590. London, UK: National Institute for Health and Care Excellence; 2017. Available at: <https://www.nice.org.uk/guidance/ipg590>. Accessed on May 31, 2019.